Refine by
Immune Development Articles & Analysis
35 news found
BioZyme’s mission is to provide an undeniable positive impact on the health and wellness of the animals it serves. Therefore, BioZyme and its staff continually research and create products to help animals and maximize efficiencies for producers. With our mission and commitment to care that comes full circle in mind, we are excited to introduce VitaFerm® Sure Start Gel. VitaFerm Sure ...
This premier event, held May 3-7, 2024, at McCormick Place in Chicago, IL, brought together renowned researchers from around the world to share the latest developments in immunology. As an exhibitor at booth #512, Creative BioMart highlighted its extensive range of products designed to support immunology research. The company's portfolio includes immune ...
Some species of Fusarium can also cause a host of infections. People with healthy immune systems may develop infections of the nails or cornea. There have even been past investigations by the Centers for Disease Control and Prevention of outbreaks of Fusarium keratitis that were associated with contaminated eye products. People with weakened ...
Melbourne, Australia, 09 January 2023 – Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted Chinese patent ZL 201680069543.6, entitled “Genetically modified cells and uses thereof”. ...
Secreted proteins are a proven class of biologics with tremendous therapeutic potential, as they regulate tissue repair and regeneration, organ development, and immune response to disease. However, despite the remarkable impact of FDA-approved biologics based on secreted proteins such as insulin, human growth hormone, and erythropoietin, this class of biologics ...
CD Bioparticles now offers more choices for researchers to choose from and use in lipid system applications, such as Ceramides, Sphingosines, Sphingomyelin, Glycosphingolipids, Phosphosphingolipids, Sphingolipid Metabolism, and Phytosphingosine & Derivatives. CD Bioparticles has developed various Lipid System for research use, which can be applied in drug delivery, tracking ...
Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncology Scientific Advisory Board to provide guidance on the Company’s development strategy across assets and assessment of emerging technologies Heidelberg, Germany, June 30, 2022 – Affimed N.V. ...
MiLaboratories, the global leader in immunome profiling software development, today announced the release of a new version of its flagship product, MiXCR 4.0. MiXCR 4.0 is enhanced software for analysis of genomics data and building a comprehensive picture of the immune response. Leading pharmaceutical research and development (R&D) teams ...
All of these new products are produced using standardized production processes to ensure the highest quality. Tests developed using these reagents can assist researchers in routine diagnostics and NiV vaccine development. ...
Human milk is the best food for newborns and developing infants, and its unique function is irreplaceable by other dairy products. ...
Over the past decade, immunotherapy has become one of the mainstays of cancer treatment, thanks in large part to monoclonal antibodies targeting the immune checkpoint protein PD-1 or its major ligand PD-L1 (mAbs). Due to abnormal immune surveillance mediated by immune checkpoints, tumor cells develop immune ...
Prellis will receive from Bristol Myers Squibb an undisclosed up-front payment, funding for research activities, development, sales milestones and royalties for licensed antibodies. "With industry leading speed, the EXIS platform provides high affinity antibodies, derived from lymph node organoids printed with Prellis’ foundational technology, using human PBMCs," said ...
“We are extremely excited about the technology Prellis has developed and were delighted to support this investment,” said Marks. ...
“We are extremely excited about the technology Prellis has developed and were delighted to support this investment,” said Marks. ...
Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. ...
A unique technology to fight the virus The inhalation treatment developed by Immune Biosolutions allows antibodies to pass through the respiratory tract and directly access the lungs to act as a viral extinguisher. ...
With a recently closed $60 million funding round, the acquisition of software company Dropprint Genomics, and additions to its leadership team, immune profiling firm Immunai is looking to expand its functional genomics capabilities to more directly inform immune therapy development and application. ...
ByImmunai
"Lilly continues to seek out novel methods for developing new medicines, and Biolojic's multi-specific antibody platform is a promising approach," said Ruth Gimeno, Ph.D., vice president of diabetes and metabolic research at Lilly. "We look forward to working closely with the scientific team at Biolojic and leveraging their expertise to discover and develop a ...
” “This research collaboration with Biolojic allows us to leverage their unique computational capabilities and assets in order to investigate a new target in the potential treatment of auto-immune disease,” said Jonathan Zalevsky, Chief Research and Development Officer of Nektar. ...
The new laboratory, established with the support of Biosceptre, will enable BIF to fast-track analytical and process development capabilities and support the Australian bio-processing sector at a critical time in the sector’s growth. ...